In vivo CAR T-cell Market Size is predicted to grow at a 32.9% CAGR during the forecast period for 2025-2034.
In vivo CAR T-cell therapy is a promising development in cancer immunotherapy, enabling the genetic modification of a patient’s T cells within the body to target cancer cells. Unlike traditional CAR T-cell therapies, which require extracting, modifying, and reinfusing T cells in a lab, in vivo methods use viral vectors (such as lentiviruses or AAV) or non-viral delivery systems (like lipid nanoparticles) to deliver CAR-encoding genes directly to immune cells. This technique enables for either long-term CAR expression or transient expression for regulated, repeated treatments.
The key market drivers for in vivo CAR T-cell therapy are shorter treatment times and cost efficiencies. This strategy speeds up treatment delivery by eliminating complex cell manufacturing and logistics, which are critical for rapidly growing malignancies. Furthermore, reducing dependency on lab-based methods reduces production costs and improves scalability, increasing patient access and presenting in vivo CAR T-cell therapy as a breakthrough oncology treatment.
Competitive Landscape
Some of the Key Players in In vivo CAR T-cell Market:
The In vivo CAR T-cell market is segmented by delivery systems and targets. By delivery systems, the market is segmented into lipid nanoparticles (LNPs), viral vectors, and oncolytic viruses. By target indication market is segmented into hematological cancers, solid tumors, non-oncology. By Target Antigen segment is categorized into CD19, BCMA, CD20, CD22, Others. By End User segment the market is segmented into Hospitals, Cancer Treatment Centers, Outpatient Clinics. The Payload Type segment comprises DNA-Based, mRNA-Based, Circular RNA (oRNA).
Viral vectors presently dominate the in vivo CAR T-cell market because of their excellent transfection efficiency, targeted delivery capability, and known safety profiles. Lentiviruses, retroviruses, and adeno-associated viruses (AAV) have been designed to selectively deliver CAR genes to T cells by modifying their envelope proteins or including targeting ligands. Their efficacy has been confirmed in preclinical and clinical trials, where lentiviral vectors expressing CD8+ or CD3+ T-cell-targeting transgenes effectively produced functional CAR T cells that proliferated and caused tumor regression in animal models.
AAV vectors have also demonstrated strong in vivo antitumor activity. Moreover, viral vectors enjoy scalable production through transient transfection in producer cell lines such as HEK-293T, and they possess an established regulatory record with multiple FDA-approved gene therapies, thus being a trusted and well-accepted platform for in vivo CAR T-cell applications.
The hematological cancers segment is the most rapidly growing and leading segment in the in vivo CAR T-cell market, primarily because of the early and successful use of CAR T-cell therapies in the treatment of blood cancers such as B-cell lymphomas, acute lymphoblastic leukemia (ALL), and multiple myeloma. These treatments have demonstrated robust clinical effectiveness, with several FDA-approved agents targeting antigens like CD19, resulting in sustained responses in patients with relapsed or refractory disease. Expansion in this segment is also driven by high unmet medical need, increasing global incidence of hematologic malignancies, and continued research focused on improving CAR T-cell persistence, safety, and accessibility through the expansion of clinical trials.
North America now dominates the in vivo CAR T-cell market with the highest proportion of revenue share and innovation activity, fueled by its strong R&D infrastructure, particularly in the U.S., which has a high concentration of research institutions, biotech companies, and clinical trial sites specializing in CAR T-cell research.
The area is supported by a robust commercial foundation, favorable regulatory environments such as fast-track FDA routes, and positive reimbursement policies that drive the development and uptake of new therapies. Moreover, North America leads in the number of active clinical trials for in vivo CAR T-cell platforms and has an established healthcare infrastructure with specialized cancer treatment facilities that can adopt sophisticated immunotherapies.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 32.9 % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Delivery Systems, Target indication and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Byterna Therapeutics, Thunder Biotech, Singular Immune, NanoCell Therapeutics, Jenthera Therapeutics, Acuitas Therapeutics, EsoBiotec (AstraZeneca), CDR3 Therapeutics, Everest Medicines, Mustang Bio, Novartis, Capstan Therapeutics, Myeloid Therapeutics, CARISMA Therapeutics, Legend Biotech, Innorna, Genocury Biotech, Abintus Bio, Moderna, Strand Therapeutics, Coastar Therapeutics, A Sail Biomedicines, Orna Therapeutics, Nona Biosciences, Interius BioTherapeutics, TriArm Therapeutics, Sanofi, AbbVie, Shanghai Simnova Biotech, Umoja Biopharma, Astellas (Xyphos Biosciences), Theorna, Kelonia Therapeutics, Pregene, Alaya.bio, EXUMA Biotech, Sana Biotechnology, Velvet Therapeutics, Deliver Biosciences, Vyriad, Imanis Life Sciences, CancerVAX, IASO Bio, Ensoma. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global In vivo CAR T-cell Media Market Snapshot
Chapter 4. Global In vivo CAR T-cell Media Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.9. Use/impact of AI on In vivo CAR T-cell Media Market Industry Trends
4.10. Global In vivo CAR T-cell Media Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. In vivo CAR T-cell Media Market Segmentation 1: By Delivery Systems, Estimates & Trend Analysis
5.1. Market Share by Delivery Systems, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Systems:
5.2.1. Lipid Nanoparticles (LNPs)
5.2.2. Viral Vectors
5.2.3. Oncolytic Viruses
Chapter 6. In vivo CAR T-cell Media Market Segmentation 2: By Targets, Estimates & Trend Analysis
6.1. Market Share by Targets, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the
following Targets:
6.2.1. Hematological Cancers
6.2.2. Solid Tumors
6.2.3. Non-Oncology
Chapter 7. Plant-Based Vaccines Market Segmentation 3: By Target Antigen, Estimates & Trend Analysis
7.1. Market Share by Target Antigen, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Antigen:
7.2.1. CD19
7.2.2. BCMA
7.2.3. CD20
7.2.4. CD22
7.2.5. Others
Chapter 8. Plant-Based Vaccines Market Segmentation 4: By End-User, Estimates & Trend Analysis
8.1. Market Share by End-User, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
8.2.1. Hospitals
8.2.2. Cancer Treatment Centers
8.2.3. Outpatient Clinics
Chapter 9. Plant-Based Vaccines Market Segmentation 4: By Payload Type, Estimates & Trend Analysis
9.1. Market Share by Payload Type, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Payload Type:
9.2.1. DNA-Based
9.2.2. mRNA-Based
9.2.3. Circular RNA (oRNA)
Chapter 10. Plant-Based Vaccines Market Segmentation 4: Regional Estimates & Trend Analysis
10.1. Global Plant-Based Vaccines Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.2.3. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.2.4. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.2.5. North America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3. Europe
10.3.1. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.3.3. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.3.4. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.3.5. Europe Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.4.3. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.4.4. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.4.5. Asia Pacific Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5. Latin America
10.5.1. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.5.3. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.5.4. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.5.5. Latin America Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Delivery Systems, 2021-2034
10.6.3. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
10.6.4. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Target Antigen, 2021-2034
10.6.5. Middle East & Africa Plant-Based Vaccines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Byterna Therapeutics
11.2.2. Thunder Biotech
11.2.3. Singular Immune
11.2.4. NanoCell Therapeutics
11.2.5. Jenthera Therapeutics
11.2.6. Acuitas Therapeutics
11.2.7. EsoBiotec (AstraZeneca)
11.2.8. CDR3 Therapeutics
11.2.9. Everest Medicines
11.2.10. Mustang Bio
11.2.11. Novartis
11.2.12. Capstan Therapeutics
11.2.13. Myeloid Therapeutics
11.2.14. CARISMA Therapeutics
11.2.15. Legend Biotech
11.2.16. Innorna
11.2.17. Genocury Biotech
11.2.18. Abintus Bio
11.2.19. Moderna
11.2.20. Strand Therapeutics
11.2.21. Coastar Therapeutics
11.2.22. A Sail Biomedicines
11.2.23. Orna Therapeutics
11.2.24. Nona Biosciences
11.2.25. Interius BioTherapeutics
11.2.26. TriArm Therapeutics
11.2.27. Sanofi
11.2.28. AbbVie
11.2.29. Shanghai Simnova Biotech
11.2.30. Umoja Biopharma
11.2.31. Astellas (Xyphos Biosciences)
11.2.32. Theorna
11.2.33. Kelonia Therapeutics
11.2.34. Pregene
11.2.35. Alaya.bio
11.2.36. EXUMA Biotech
11.2.37. Sana Biotechnology
11.2.38. Velvet Therapeutics
11.2.39. Deliver Biosciences
11.2.40. Vyriad
11.2.41. Imanis Life Sciences
11.2.42. CancerVAX
11.2.43. IASO Bio
11.2.44. Ensoma
In vivo CAR T-cell Market by Delivery Systems -
In vivo CAR T-cell Market by Targets -
In vivo CAR T-cell Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
